Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Iromed Group is a South Korean biotechnology and healthcare company that specializes in the integration of nutritional science and advanced medical therapies. Founded in 2001 by Dr. Seong-Joo Hwang, the company operates as the research and medical arm of the larger Irom Group. Its primary focus is the development of immune cell therapies, specifically Natural Killer (NK) and Cytokine-Induced Killer (CIK) cell treatments for various cancers. Additionally, Iromed conducts extensive research into natural product-derived therapeutics, such as the ER-7 compound for bone health and osteoporosis. The company also manages specialized clinics that provide holistic and integrative care for cancer patients, combining conventional medicine with immune-boosting protocols. Through its Total Health Care approach, Iromed Group aims to provide comprehensive solutions for disease prevention and regenerative medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Iromed Group.